Optimal pharmacological management of HCM by clinical manifestations
Pablo Garcia-Pavia, MD, PhD
Evidence-based novel therapies in HCM
Michelle Michels, MD
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
James Januzzi, MD
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
Javed Butler, MD
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.